In another study, Gros et al. (49) demonstrated that PD-1 expression on CD8+ TILs in fresh melanoma tumor specimens enabled identification of a diverse patient-specific repertoire of clonally expanded tumor-reactive cells, including mutated neoantigen-specific CD8+ lymphocytes. This evidence concerns the gene CD8A and melanoma.